One of the more spurious and naive arguments proffered by the industry's antagonists and even some people in government is that the pricing of new treatments should reflect whether public funding contributed in any way to its development.
Latest Video
New Stories
-
Wesfarmers Health emerges as growth engine after delivering strong first half
February 19, 2026 - - Australian Biotech -
Telix files for European approval of brain cancer imaging candidate TLX101-Px
February 18, 2026 - - Australian Biotech -
IDT signals turnaround as revenue rises and losses narrow under strategic reset
February 18, 2026 - - Latest News -
Nyrada advances lead candidate into mid-stage trial as momentum builds across programs
February 18, 2026 - - Australian Biotech -
AusBiotech–Proto Axiom alliance aims to fast-track Australia’s next wave of biotech innovators
February 18, 2026 - - Latest News -
Novo Nordisk backs community-led initiative that aims to transform life for Logan’s children
February 18, 2026 - - Latest News -
CSL and Lilly strike strategic deal to advance promising anti-inflammatory therapy
February 18, 2026 - - Latest News

